Literature DB >> 33144475

Plan-Optimization Method for Central-shielding Pelvic Volumetric-modulated Arc Therapy for Cervical Cancer.

Ryuta Hirai1, Tomoaki Tamaki2,3, Mitsunobu Igari2, Y U Kumazaki2, Shin-Ei Noda2, Shingo Kato2.   

Abstract

AIM: To establish a method of plan optimization in pelvic volumetric-modulated arc therapy (VMAT) for cervical cancer using the central-shielding (CS) principle. PATIENTS AND METHODS: We created external beam VMAT plans for eight cases with non-bulky stage I-IIb using the CS principle based on the Japanese standard guideline. Clinical target volumes (CTVs) for whole-pelvis (WP) irradiation were created using published guidelines, and CTVs for CS irradiation were created by subtracting the uterus corpus and 4 cm-wide regions centered at the cervix and vagina from the CTVs for WP irradiation. For plan optimization of CS irradiation, a 4-cm diameter cylindrical volume centered in the cervix and vagina was created as the volume receiving a high dose in brachytherapy, and the volume overlapping with the rectum was defined as the Ant-Rectum. Dose-volume histogram (DVH) parameters of two CS VMAT plans with and without (VMATOPT/VMATNO) dose optimization to the Ant-Rectum were compared.
RESULTS: VMATOPT plans resulted in significantly lower DVH parameters of the Ant-Rectum and rectum compared to VMATNO plans. These were comparable to the DVH parameters of three-dimensional conformal radiotherapy (3DCRT) plans. Both VMAT plans resulted in significantly better coverage of planning target volumes than did the 3DCRT plans.
CONCLUSION: In the implementation of IMRT/VMAT as the standard treatment for cervical cancer in Japan, our optimization method may be an essential step toward fully benefitting from the CS principle. Copyright
© 2020, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Entities:  

Keywords:  Cervical cancer; central-shielding; intensity-modulated radiation therapy; rectal toxicity; volumetric-modulated arc therapy

Mesh:

Year:  2020        PMID: 33144475      PMCID: PMC7811628          DOI: 10.21873/invivo.12206

Source DB:  PubMed          Journal:  In Vivo        ISSN: 0258-851X            Impact factor:   2.155


  24 in total

1.  Long-term results of high-dose rate intracavitary brachytherapy for squamous cell carcinoma of the uterine cervix.

Authors:  Takashi Nakano; Shingo Kato; Tatsuya Ohno; Hirohiko Tsujii; Shinichiro Sato; Kenjiro Fukuhisa; Tatsuo Arai
Journal:  Cancer       Date:  2005-01-01       Impact factor: 6.860

2.  Dose effect relationship for late side effects of the rectum and urinary bladder in magnetic resonance image-guided adaptive cervix cancer brachytherapy.

Authors:  Petra Georg; Richard Pötter; Dietmar Georg; Stefan Lang; Johannes C A Dimopoulos; Alina E Sturdza; Daniel Berger; Christian Kirisits; Wolfgang Dörr
Journal:  Int J Radiat Oncol Biol Phys       Date:  2011-02-23       Impact factor: 7.038

3.  A consensus-based guideline defining the clinical target volume for pelvic lymph nodes in external beam radiotherapy for uterine cervical cancer.

Authors:  Takafumi Toita; Tatsuya Ohno; Yuko Kaneyasu; Takashi Uno; Ryouichi Yoshimura; Takeshi Kodaira; Kazuhisa Furutani; Goro Kasuya; Satoshi Ishikura; Toshiharu Kamura; Masahiro Hiraoka
Journal:  Jpn J Clin Oncol       Date:  2010-02-04       Impact factor: 3.019

4.  Simultaneous integrated boost (SIB) of the parametrium and cervix in radiotherapy for uterine cervical carcinoma: a dosimetric study using a new alternative approach.

Authors:  Jen-Yu Cheng; Eng-Yen Huang; Shun-Neng Hsu; Chong-Jong Wang
Journal:  Br J Radiol       Date:  2016-10-06       Impact factor: 3.039

5.  Clinical outcomes of definitive intensity-modulated radiation therapy with fluorodeoxyglucose-positron emission tomography simulation in patients with locally advanced cervical cancer.

Authors:  Elizabeth A Kidd; Barry A Siegel; Farrokh Dehdashti; Janet S Rader; Sasa Mutic; David G Mutch; Matthew A Powell; Perry W Grigsby
Journal:  Int J Radiat Oncol Biol Phys       Date:  2009-10-31       Impact factor: 7.038

6.  Dosimetric comparison of intensity-modulated solutions for intact prostate cancer.

Authors:  Cory J Neill
Journal:  Med Dosim       Date:  2014-08-08       Impact factor: 1.482

7.  Dose-volume histogram analysis of composite EQD2 dose distributions using the central shielding technique in cervical cancer radiotherapy.

Authors:  Tomoaki Tamaki; Shin-Ei Noda; Tatsuya Ohno; Yu Kumazaki; Shingo Kato; Takashi Nakano
Journal:  Brachytherapy       Date:  2016-07-27       Impact factor: 2.362

8.  Phase II study of concurrent chemoradiotherapy with high-dose-rate intracavitary brachytherapy in patients with locally advanced uterine cervical cancer: efficacy and toxicity of a low cumulative radiation dose schedule.

Authors:  Takafumi Toita; Ryo Kitagawa; Tetsutaro Hamano; Kenji Umayahara; Yasuyuki Hirashima; Yoichi Aoki; Masahiko Oguchi; Mikio Mikami; Ken Takizawa
Journal:  Gynecol Oncol       Date:  2012-04-30       Impact factor: 5.482

9.  Preliminary analysis of chronic gastrointestinal toxicity in gynecology patients treated with intensity-modulated whole pelvic radiation therapy.

Authors:  Arno J Mundt; Loren K Mell; John C Roeske
Journal:  Int J Radiat Oncol Biol Phys       Date:  2003-08-01       Impact factor: 7.038

10.  Dosimetric comparison of three-dimensional conformal radiotherapy versus volumetric-arc radiotherapy in cervical cancer treatment: applying the central-shielding principle to modern technology.

Authors:  Tomoaki Tamaki; Ryuta Hirai; Mitsunobu Igari; Yu Kumazaki; Shin-Ei Noda; Yoshiyuki Suzuki; Shingo Kato
Journal:  J Radiat Res       Date:  2018-09-01       Impact factor: 2.724

View more
  1 in total

Review 1.  Combined Interstitial and Intracavitary High-Dose Rate Brachytherapy of Cervical Cancer.

Authors:  Jun Itami; Naoya Murakami; Miho Watanabe; Shuhei Sekii; Takahiro Kasamatsu; Shingo Kato; Hisako Hirowatari; Hitoshi Ikushima; Ken Ando; Tatsuya Ohno; Hiroyuki Okamoto; Kae Okuma; Hiroshi Igaki
Journal:  Front Oncol       Date:  2022-01-13       Impact factor: 6.244

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.